Full Printable Schedule-at-a-Glance (Updated: 8/29/14)
Preconference Activity—Facility Tours
8:00 a.m.–5:00 p.m.
Conference and Exhibitor Registration—5th Floor Registration
Lunch—Exhibit Hall, Chicago Ballroom, 5th Floor
Welcome and Opening Remarks—Grand Ballroom, 7th Floor
Keynote Address: The Repressed Role of Adverse Childhood Experiences in Adult Medical Care and Costs, Vincent J. Felitti, MD, University of California
The Adverse Childhood Experiences (ACE) study was funded by the Centers for Disease Control and Prevention (CDC) and is one of the largest investigations ever conducted to assess the relationship between childhood trauma and adult well-being. Traumatic childhood experiences have been linked to a variety of changes in brain structure and function. With a specific focus on childhood abuse, neglect, and family dysfunction, data collected from the ACE study suggests that certain experiences are major risk factors for the leading causes of illness and death. This session will explore the results of the ACE study and emphasize that prevention of some of our nation’s worst health and social problems might start with understanding that these issues might be consequences of adverse childhood experiences.
Bariatric Surgery for the Management of Type 2 Diabetes in Obese Patients, Sayeed Ikramuddin, MD, University of Minnesota
Obesity has been declared a disease by the American Medical Association and is, in itself, a major medical risk that predisposes to other chronic conditions. Obesity paired with type 2 diabetes significantly increases the risk of cardiovascular disease, heart attack, stroke and other comorbidities associated with diabetes. Weight loss surgery is increasingly being used as a tool to manage type 2 diabetes. This session will discuss the question “can diabetes be surgically cured?” Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus will be presented.
Advances in the Management of Intestinal Failure, George V. Mazariegos, MD, FACS, Children’s Hospital of Pittsburgh of UPMC
An intestinal transplant is a last-resort treatment option for patients with intestinal failure who develop life-threatening complications from total parenteral nutrition (TPN). Recent advances in small bowel transplantation and nontransplant surgical techniques now offer hope of sustained survival in the future without parenteral nutrition. This session will discuss the long-term complications, as well as the clinical and financial challenges associated with intestinal failure.
Living Donor Liver Transplant: Update on Status and Current Outcomes, John R. Lake, MD, University of Minnesota Medical Center, Fairview
The most effective therapy for end-stage liver disease is transplantation. Improved surgical techniques and the introduction of new immunosuppressive agents have enhanced the long-term results of liver transplantation, leading to an increased demand for liver transplantation that exceeds the number of potential donor organs. Liver transplantation from living donors (LDLT) is currently the most effective alternative to overcome the problem of organ shortage for adults. This session will discuss the current role of LDLT, and the surgical techniques and recipient outcomes.
Welcome Reception and Exhibit Grand Opening—Chicago Ballroom, 5th Floor
Wellness Screenings and Flu Vaccinations
7th Annual Wellness Walk
Registration and Continental Breakfast—7th Floor
Updates in Liver and Kidney Allocation Algorithms, David C. Mulligan, MD, FACS, Yale School of Medicine
Despite a steady increase in the number of kidney and liver transplants performed each year in the United States, there remains a significant shortage of kidneys and livers available for transplant. This has necessitated the development of allocation schema whereby priority for donor organs is given to the most severely ill patients. This session will discuss changes in the allocation policy that have been made specifically to improve equitable access to livers and kidneys for transplant.
What Is the Status of Personalized Immunosuppression? Michael Abecassis, MD, MBA, Northwestern University Feinberg School of Medicine
Long-term graft and patient survival are the key issues in transplantation. Liver transplantation is potentially a curative treatment for hepatocellular carcinoma (HCC). However, disease recurrence is the main challenge to the success of this treatment. Immunosuppressants that are universally used after transplantation to prevent graft rejection could potentially have a significant impact on HCC recurrence. This session will discuss the potential effects of different types of immunosuppressants on HCC recurrence and the role of personalized immunosuppressants used for patients transplanted with HCC.
A New Approach for Evaluating Renal Function and Predicting Risk, William McClellan, MD, Emory University
Currently, kidney disease severity can be classified by estimated glomerular filtration rate (GFR) and albuminuria, but more accurate information regarding risk for progression to kidney failure is required for clinical decisions about testing, treatment, and referral. A new, international study from the Chronic Kidney Disease (CKD) Prognosis Consortium found that use of blood levels of cystatin C to estimate kidney function—alone or in combination with creatinine—strengthens the association between kidney function and risks of death and end-stage renal disease. This session will discuss better methods for identifying the subset of patients who are at the highest risk of adverse outcomes and how this could be useful for clinicians and other decision makers.
Luncheon Presentation (nonaccredited/optional)—Grand Ballroom
Dessert Reception—Exhibit Hall, Chicago Ballroom, 5th Floor
Trends in the Treatment of Multiple Myeloma, Sagar Lonial, MD, Emory University
Acute Lymphoblastic Leukemia (ALL) in Children: Recent Findings, Nobuko Hijiya, MD, Ann & Robert H. Lurie Children’s Hospital of Chicago
ALL is the most common cancer in children and is among the most curable of the pediatric malignancies. Many clinical, biological, genetic, and molecular features have been identified as having prognostic significance in the outcome of patients with ALL. Prognostic features play a critical role in directing therapy for ALL and as scientific and treatment advances are made, this area of investigation changes rapidly. This session will discuss the importance of prognostic factors that may influence the treatments used for patients with ALL, as well as review treatment protocols designed to reduce toxicity while preserving efficacy for ALL patients.
Managing Long-Term Complications After Hematopoietic Stem Cell Transplantation (HSCT), Matthew Carabasi, MD, Thomas Jefferson University Hospital
HSCT is a medical procedure that is often performed on patients with certain cancers of the blood or bone marrow, such as multiple myeloma or leukemia. The HSCT procedure involves the transplantation of multipotent hematopoietic stem cells, which are usually derived from bone marrow, peripheral blood, or umbilical cord blood using the patient’s own stem cells or those obtained from a healthy donor. HSCT is one of the revolutionary discoveries of medicine leading to the cure of many of the hematological malignancies and for several nonmalignant conditions. Despite all HSCT’s advances, it still remains a procedure with several potential complications, with infection being one of the major issues. This session will discuss managing long-term complications post HSCT procedure with a focus on complications from bacterial, parasitic, fungal and viral infectious diseases.
Closing Reception—Exhibit Hall, Chicago Ballroom, 5th Floor
Continental Breakfast—7th Floor Foyer
Preventing and Managing Chronic Conditions: Strategies to Engage and Empower Consumers to Actively Participate in Their Health Care! Victor J. Strecher, PhD, MPH, University of Michigan
Effectively engaging consumers in healthy behavior change is critical to both their health and well-being. Healthy behavior modifications and the personal choices people make for themselves have a profound influence on the state of their health. The increasing prevalence of largely preventable chronic conditions and the suboptimal use of health care resources are strongly influenced by the behavioral choices made by consumers. While most people know what they need to do to improve their health, more often than not, they fall short when it comes to taking effective action. This session will discuss the powerful forces that impede the achievement of health care goals.
The Effects of the Affordable Care Act on Stem Cell Transplant (SCT), Alicia Silver, MPP, National Marrow Donor Registry (NMDP)/Be the Match
Our current health care environment is complex with new laws and changes. The Patient Protection and Affordable Care Act, commonly called the Affordable Care Act (ACA), was signed into law in 2010, with most of the health care provisions going into effect during 2014. The ACA was designed to increase access, improve quality, and control health care costs. As a result of the ACA, SCT patients may be impacted more quickly and to a greater degree than average health care consumers. This presentation will discuss how the ACA will impact SCT patients and the role it plays from patients’ and providers’ perspectives.
Prize Drawings & Break—Grand Ballroom, 7th Floor
Infertility: Elective Single-Embryo Transfer (eSET), Mark Leondires, MD, Reproductive Medicine Associates of Connecticut
Infertility is a fairly common occurrence, wherein about 15 percent of couples are unable to conceive after six months to one year of attempting pregnancy. There are medical treatments that are specific to assist infertile couples with conception, such as in vitro fertilization (IVF). IVF involves the transfer of an embryo into a woman’s uterus with the hopes of leading to a healthy pregnancy. Despite a significant push from the American Society for Reproductive Medicine (ASRM) promoting eSET, more than 85 percent of IVF successes are as a result of the transfer of multiple embryos, with the attended risk of a multiple gestation. This session will review the infertility standard of care pathway, the benefits of eSET and strategies to increase the use of eSET.
Ventricular Assist Devices (VADs): Utilization, Management, and Clinical and Financial Outcomes, Scott C. Silvestry, MD, Barnes-Jewish Hospital
Although heart transplants are considered the gold standard of treatment for advanced heart failure, the incidence of transplant is limited due to stringent selection criteria and the scarcity of acceptable donors. Because of this, VADs are showing trends of increasing utilization, expanding the previously limited scope of treatment options for patients with advanced heart failure.
While successful VAD implantation has many potential benefits it also carries risks and posttransplant case management is key for effective utilization. This session will discuss the complexity of patient management, patient selection, prior authorization, costs implications and outcomes.
Note: OptumHealth Education reserves the right to make any necessary changes to this program. Efforts will be made to keep presentations as scheduled. However, unforeseen circumstances may result in the substitution of faculty or content.
Last Updated: 8/29/2014